Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484234 | 0.77 | KDM5B (0.47) | KDM5BKDM4EALDH1A1HPGDGFER | |
| SCHEMBL4586569 | 0.77 | GSK3B (0.44) | — | |
| SCHEMBL6021715 | 0.71 | BRD4 (0.31) | — | |
| SCHEMBL3325823 | 0.62 | KDM4E (0.47) | KDM5BKDM4EALDH1A1HPGD | |
| SCHEMBL7015921 | 0.61 | KDM4E (0.54) | KDM4EALDH1A1HPGD | |
| SCHEMBL11779144 | 0.61 | KDM4E (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL18210595 | 0.60 | AXL (0.44) | KDM4EALDH1A1GRM5 | |
| SCHEMBL18776508 | 0.60 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL30473299 | 0.60 | ADORA3 (0.36) | ADORA3 | |
| SCHEMBL10994895 | 0.60 | KDM4E (0.43) | KDM5BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480981-B1 | 1-(ALKYL), 1-(HETEROARYL)ALKYL AND 1-[(ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMIDAZO[1,2-A]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | claimed |
| US-20050119280-A1 | 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives | SANOFI (FR) | 2005-06-02 | — | — | US | claimed |
| EP-1480981-A1 | 1-(ALKYL), 1-(HETEROARYL)ALKYL AND 1-[(ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMIDAZO[1,2-A]PYRIMIDIN-5(1H)-ONE DERIVATIVES | Sanofi-Aventis (FR) | 2004-12-01 | — | — | EP | claimed |
| WO-2003072580-A1 | 1-[ALKYL], 1-[HETEROARYL)ALKYL] AND 1-[ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMADAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2003-09-04 | — | — | WO | claimed |
| US-20080318980-A1 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-12-25 | — | — | US | disclosed |
| US-7429663-B2 | 7-(Pyrimidin-4-yl)-Imidazo[1,2-a]Pyrimidin-5(1H)-ones as GSK3β inhibitors | SANOFI-AVENTIS (FR) | 2008-09-30 | — | — | US | disclosed |
| EP-1480981-B1 | 1-(ALKYL), 1-(HETEROARYL)ALKYL AND 1-[(ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMIDAZO[1,2-A]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | disclosed |
| US-20050119280-A1 | 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives | SANOFI (FR) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318980-A1 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS | GSK3B, GSK3A, PSEN1 | KDM5B 1320/4885KDM4E 1428/4885ALDH1A1 1041/4885 |
| US-20050119280-A1 | 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives | PSEN1, GSK3A, GSK3B | KDM5B 2913/4885KDM4E 2616/4885ALDH1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.